ANI Pharmaceuticals | ANIP - Interest Expense On Debt


ANI Pharmaceuticals reported $4.41M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Aurora Cannabis CAD 230K 1.88M Mar/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Heron Therapeutics USD 600K 100K Dec/2024
Hikma Pharmaceutical USD 67M 47M Dec/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Perrigo USD 7.98B 7.94B Mar/2026
Sun Pharmaceuticals INR 859M 139.6M Mar/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026